Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10144795 | 0.87 | SYK (0.41) | USP30GPR119ALOX5APFEN1HCRTR1 | |
| SCHEMBL10145584 | 0.86 | GRM5 (0.36) | ALDH1A1GRM5LMNAMEN1MAPT | |
| SCHEMBL7859303 | 0.83 | ALDH1A1 (0.38) | ALDH1A1GRM5LMNAMEN1MAPT | |
| SCHEMBL10145590 | 0.81 | CHRNA3 (0.37) | ALDH1A1GRM5GPR119ALOX5APFEN1 | |
| SCHEMBL10144799 | 0.78 | GPR119 (0.36) | LMNANPSR1GPR119ALOX5APFEN1 | |
| SCHEMBL10145625 | 0.78 | HCRTR1 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL10145425 | 0.77 | GPR119 (0.36) | GPR119ALOX5APFEN1 | |
| SCHEMBL10144962 | 0.76 | HCRTR1 (0.39) | GPR119ALOX5APFEN1HCRTR1 | |
| SCHEMBL29007871 | 0.75 | NPSR1 (0.49) | ALDH1A1LMNAMEN1MAPTKMT2A | |
| SCHEMBL10144711 | 0.75 | HCRTR1 (0.50) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | ALDH1A1 548/4885GRM5 149/4885LMNA 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.